CervoMed (NASDAQ:CRVO) Raised to Sell at Wall Street Zen

CervoMed (NASDAQ:CRVO) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of CervoMed in a research note on Wednesday, August 12th. Roth Capital set a $9.00 price target on shares of CervoMed in a report on Monday, May 18th. Chardan Capital raised shares of CervoMed to a “strong-buy” rating in a research note on Monday, August 3rd. Weiss Ratings downgraded shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CervoMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

CervoMed Stock Performance

Shares of CRVO stock opened at $2.73 on Friday. CervoMed has a 12 month low of $2.13 and a 12 month high of $11.25. The stock has a market cap of $41.28 million, a P/E ratio of -0.85 and a beta of -0.63. The company has a 50 day simple moving average of $3.11 and a two-hundred day simple moving average of $3.73.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.22. CervoMed had a negative net margin of 672.80% and a negative return on equity of 156.02%. As a group, equities analysts forecast that CervoMed will post -2.4 earnings per share for the current year.

Insiders Place Their Bets

In other CervoMed news, Director Joshua S. Boger acquired 955,414 shares of the stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $3.14 per share, for a total transaction of $2,999,999.96. Following the completion of the transaction, the director directly owned 1,795,865 shares of the company’s stock, valued at $5,639,016.10. This trade represents a 113.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 35.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CervoMed

Large investors have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in shares of CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after buying an additional 1,526 shares during the period. Marshall Wace LLP bought a new stake in shares of CervoMed in the 2nd quarter valued at about $76,000. XTX Topco Ltd bought a new stake in shares of CervoMed in the 4th quarter valued at about $81,000. Jane Street Group LLC bought a new position in shares of CervoMed during the fourth quarter valued at approximately $88,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of CervoMed during the fourth quarter valued at approximately $110,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed News Roundup

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts and reaffirmed its Buy rating. The firm reduced its projected loss for FY2026 to $2.32 per share from $2.70, FY2027 to $1.90 from $1.99, Q3 2026 to $0.48 from $0.60, and Q4 2026 to $0.48 from $0.59. It also improved its Q1 and Q2 2027 loss estimates to $0.46 and $0.41 per share, respectively. HC Wainwright Reaffirms Buy Rating for CervoMed
• Positive Sentiment: Brookline Capital Markets also sharply improved its loss forecasts. The firm lowered its FY2026 projected loss to $2.97 per share from $4.34, while reducing its Q3 and Q4 2026 loss estimates to $0.73 and $0.75 per share from $1.04 and $1.55, respectively. These revisions indicate expectations for better-than-previously-anticipated financial performance.
• Neutral Sentiment: The estimate changes still imply substantial ongoing losses. HC Wainwright’s forecasts remain negative for every listed quarter, and the consensus estimate for CervoMed’s current fiscal year is a $2.50-per-share loss. Investors may therefore view the revisions as incremental rather than evidence of near-term profitability.
• Negative Sentiment: Shares have decreased even with the improved outlook. CervoMed remains a small, loss-making biotechnology company, and its stock is trading below both its 50-day and 200-day moving averages. Without new clinical, regulatory, financing, or commercialization news, analyst estimate changes alone may not be enough to overcome concerns about cash needs and execution risk.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.